With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Please provide your email address to receive an email when new articles are posted on . Infections are a “small but increasing” cause of hospitalization in childhood SLE, and account for most ...

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis is a common complication of systemic lupus erythematosus. New therapies are now available with ...

Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset SLE (cSLE).Methods We conducted a retrospective cohort study of cSLE ...